Obicetrapib Advances: NewAmsterdam Pharma Reports Wider Q1 Loss, Accepted MAAs
NAMS sits 86% above its 52-week low of $16.785.
Summary
NewAmsterdam Pharma reported first-quarter 2026 results with revenue of $3.04 million, essentially flat year-over-year, and a wider net loss of $48.44 million, resulting in an EPS of ($0.40). While the widening loss is a negative financial indicator, the company announced significant operational progress for its lead product candidate, obicetrapib. This includes the completion of enrollment in the PREVAIL cardiovascular outcomes trial and the acceptance of marketing authorization applications by the EMA, UK, and Switzerland, with regulatory decisions anticipated in the second half of 2026. Positive Phase 3 topline results were also reported for other trials. For a clinical-stage biotech, these clinical and regulatory milestones are highly material, indicating significant de-risking and progress towards commercialization, which could offset the financial burn. Investors will be watching for the interim DSMB analysis for PREVAIL in Q4 2026 and the upcoming regulatory decisions.
At the time of this announcement, NAMS was trading at $31.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $16.79 to $42.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.